Although many big pharmas have abandoned the clinically and commercially challenging field of antibiotics, Merck & Co. Inc. is one of the few continuing to invest in early-stage R&D in the therapeutic area. But developing novel antibiotic approaches beyond known mechanisms is a long-term proposition that could take a decade or more to deliver, VP-Infectious Diseases Research Daria Hazuda said in an interview.
“It’s pretty clear there are fewer and fewer people in large companies working in this area, both in the antibiotic...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
